← Issue №15/ week of Oct 11, 2026/Colorectal

Population-Based Cohort Study: Colorectal Cancer Risk Stratification in Symptomatic Patients Using the Faecal Immunochemical Test, Blood Results and Patient Characteristics in Wales.

From GI Signals issue №15: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal prospective cohort · n=166,863 · Oct 9, 2026 · Aliment Pharm Ther · IF 6.7

Population-Based Cohort Study: Colorectal Cancer Risk Stratification in Symptomatic Patients Using the Faecal Immunochemical Test, Blood Results and Patient Characteristics in Wales.

New evidencecolorectal cancercolorectal cancer screeningbiomarkerepidemiology
Clinical takeawayUse IDA as an additional risk stratification factor in symptomatic women <50 years with FIT ≥10 μgHb/g, as it significantly increases CRC risk compared to those without IDA.
What it foundIn symptomatic women <50 years with FIT ≥10 μgHb/g, CRC risk was 6.45% (95% CI: 3.52-9.29) with IDA vs 2.20% (95% CI: 1.57-2.83) without IDA.
ContextRefines current FIT-based CRC risk stratification by incorporating IDA, particularly in younger women, where CRC risk is otherwise underestimated.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Malcolm FL … Humes DJ · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №15 Every paper GI Signals surfaces gets a page like this one. All issues